These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 25808511)
21. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479 [TBL] [Abstract][Full Text] [Related]
22. Simultaneous polysubstance use among Danish 3,4-methylenedioxymethamphetamine and hallucinogen users: combination patterns and proposed biological bases. Licht CL; Christoffersen M; Okholm M; Damgaard L; Fink-Jensen A; Knudsen GM; Erritzoe D Hum Psychopharmacol; 2012 Jul; 27(4):352-63. PubMed ID: 22696164 [TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics, pharmacodynamics and toxicology of new psychoactive substances (NPS): 2C-B, 4-fluoroamphetamine and benzofurans. Nugteren-van Lonkhuyzen JJ; van Riel AJ; Brunt TM; Hondebrink L Drug Alcohol Depend; 2015 Dec; 157():18-27. PubMed ID: 26530501 [TBL] [Abstract][Full Text] [Related]
24. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Verheyden SL; Henry JA; Curran HV Hum Psychopharmacol; 2003 Oct; 18(7):507-17. PubMed ID: 14533132 [TBL] [Abstract][Full Text] [Related]
25. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. Reay JL; Hamilton C; Kennedy DO; Scholey AB J Psychopharmacol; 2006 May; 20(3):385-8. PubMed ID: 16574712 [TBL] [Abstract][Full Text] [Related]
26. Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances. Simmler LD; Liechti ME Handb Exp Pharmacol; 2018; 252():143-164. PubMed ID: 29633178 [TBL] [Abstract][Full Text] [Related]
27. From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends. Edland-Gryt M; Sandberg S; Pedersen W Int J Drug Policy; 2017 Dec; 50():1-8. PubMed ID: 28869878 [TBL] [Abstract][Full Text] [Related]
28. Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users. Soar K; Parrott A; Turner J J Psychopharmacol; 2009 Sep; 23(7):745-58. PubMed ID: 18635698 [TBL] [Abstract][Full Text] [Related]
29. The rise of new psychoactive substance use in Australia. Burns L; Roxburgh A; Matthews A; Bruno R; Lenton S; Van Buskirk J Drug Test Anal; 2014; 6(7-8):846-9. PubMed ID: 24599890 [TBL] [Abstract][Full Text] [Related]
30. Party people: personality and MDMA use of house party visitors. ter Bogt TF; Engels RC; Dubas JS Addict Behav; 2006 Jul; 31(7):1240-4. PubMed ID: 16143453 [TBL] [Abstract][Full Text] [Related]
31. MDMA: interactions with other psychoactive drugs. Mohamed WM; Ben Hamida S; Cassel JC; de Vasconcelos AP; Jones BC Pharmacol Biochem Behav; 2011 Oct; 99(4):759-74. PubMed ID: 21756931 [TBL] [Abstract][Full Text] [Related]
32. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users. Uosukainen H; Tacke U; Winstock AR Int J Drug Policy; 2015 Jan; 26(1):78-83. PubMed ID: 25107829 [TBL] [Abstract][Full Text] [Related]
33. Methylone and mCPP, two new drugs of abuse? Bossong MG; Van Dijk JP; Niesink RJ Addict Biol; 2005 Dec; 10(4):321-3. PubMed ID: 16318952 [TBL] [Abstract][Full Text] [Related]
34. [The phenomenon of drug change in the interviews with injecting drug users]. Rácz J; Csák R; Faragó R; Vadász V Psychiatr Hung; 2012; 27(1):29-47. PubMed ID: 22493147 [TBL] [Abstract][Full Text] [Related]
35. Using population screening for recruitment of young adults engaged in illicit drug use: methodological issues and sampling outcomes. Smirnov A; Kemp R; Wells H; Legosz M; Najman JM Soc Sci Res; 2014 May; 45():89-97. PubMed ID: 24576629 [TBL] [Abstract][Full Text] [Related]
36. 3,4-Methylenedioxymethamphetamine (MDMA; ecstasy) use and transitions to injection drug use among street-involved youth. Lake S; Gaddis A; Tupper KW; Nosova E; DeBeck K Subst Abus; 2019; 40(3):350-355. PubMed ID: 30457939 [No Abstract] [Full Text] [Related]
37. Ecstasy (3, 4-methylenedioxymethamphetamine) use among Japanese rave population. Shimane T; Hidaka Y; Wada K; Funada M Psychiatry Clin Neurosci; 2013 Jan; 67(1):12-9. PubMed ID: 23331284 [TBL] [Abstract][Full Text] [Related]
38. Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Parrott AC; Milani RM; Parmar R; Turner JD Psychopharmacology (Berl); 2001 Dec; 159(1):77-82. PubMed ID: 11797073 [TBL] [Abstract][Full Text] [Related]
39. ['Ecstasy-light' - not as light as its name suggests: toxic effects of 4-fluoroamphetamine]. Knippels MCJ; Essers IMM; Magdelijns FJH; van Twist DJL Ned Tijdschr Geneeskd; 2017; 161():D1356. PubMed ID: 28659207 [TBL] [Abstract][Full Text] [Related]
40. Users' perceptions of the risks and effects of taking ecstasy (MDMA): a questionnaire study. Murphy PN; Wareing M; Fisk J J Psychopharmacol; 2006 May; 20(3):447-55. PubMed ID: 16574719 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]